EuroBiotech—More articles of note

(NS Newsflash/CC BY 2.0)

> Innate Pharma agreed to trial anti-C5aR monoclonal antibody IPH5401 in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi. The phase 1/2 trial will assess the effect of the combination in patients with certain types of solid tumors. Statement

> BerGenBio posted data from phase 2 trials that are administering its AXL inhibitor in combination with Merck’s Keytruda. Release 

> Helsinn Healthcare joined with Scientific Centre of Monaco to develop pharmacological inhibitors in kidney cancer. Release 

> Sanofi filed for European approval of a sleeping sickness treatment. The French pharma worked on the therapy with the Drugs for Neglected Disease Initiative. Statement

> Affimed shared data from a trial that tested NK cell engager candidate AFM13 in combination with Keytruda. Statement